Idera Pharma (IDRA) Gains on Positive Phase 1/2 IMO-2125 Clinical Trial Data
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Idera Pharma (NASDAQ: IDRA) is gaining 10% early on volume that is running 10x normal after the company reported initial clinical data from its ongoing Phase 1/2 clinical trial of intra-tumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist. In this arm of the Phase 1 portion of the trial, IMO-2125 is being evaluated in combination with ipilimumab for treatment of patients with metastatic melanoma who have failed prior PD-1 therapy. These early results indicate that IMO-2125 is demonstrating promising clinical activity and is being well tolerated in a patient population with minimal options and low expectation of clinical response with ipilimumab treatment alone.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ContraVir Pharma (CTRV) Gains on Heavy Volume
- Stocks with Implied Volatility Movement
- Rent A Center (RCII) volatility increases as shares near record low into Q3 and outlook
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!